Dawn has over 20 years of research and GMP experience in multiple scientific disciplines, with 15 years in the cell and gene therapy field. She is responsible for leading the process development and manufacturing teams at ElevateBio. She also works closely with the scientific and executive business development staff to evaluate product opportunities and lead CMC strategic planning for next generation industrial best practices.
Prior to ElevateBio, Dawn lead the cellular and viral process and analytical development teams at Unum Therapeutics, where she was responsible for development of their ACTR (antibody coupled T cell receptor) technologies. Before Unum, she spent almost 5 years at bluebird bio building out their process development capabilities and leading teams in the development and tech transfer of the bb2121 CAR T product in oncology and Lenti-D and Lenti-G products for ALD, Beta Thal and Sickle cell disease. Dawn spent 6 years working for Bruce Levine in the Clinical Cell and Vaccine Production Facility (CVPF) at University of Pennsylvania Abramson Cancer Center, where she focused on the translation and development of multiple novel manufacturing platforms in support of > 15 diverse early Phase I/II programs. She began her career at Thomas Jefferson University studying HIV and utilizing the SV40 virus for gene delivery.
Education & Accomplishments
Dawn has a Bachelor’s Degree in Biology from Catawba College and a Master of Science in Biology from Western Carolina University.
Interested in working with people like Dawn? We’re looking for pioneers and innovative thinkers committed to developing the next-generation of cell and gene therapies. Review our open roles and find your future.